Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Sign Up to like & getrecommendations! Published in 2017 at "Thorax"
DOI: 10.1136/thoraxjnl-2016-208710
Abstract: Rationale There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should be initiated. Some physicians prefer not to treat patients with preserved lung volume. Objective To investigate whether patients with IPF… read more here.
Keywords: lung volume; preserved lung; fvc predicted; volume ... See more keywords
Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years
Sign Up to like & getrecommendations! Published in 2022 at "Respiration"
DOI: 10.1159/000527308
Abstract: Background: Idiopathic pulmonary fibrosis (IPF) primarily affects old patients. Old age is a predictor of mortality. Nintedanib, the only antifibrotic drug approved in Italy for patients aged >80 years, can slow the progression of IPF… read more here.
Keywords: idiopathic pulmonary; aged years; pulmonary fibrosis; nintedanib patients ... See more keywords
Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Sign Up to like & getrecommendations! Published in 2017 at "American journal of respiratory and critical care medicine"
DOI: 10.1164/rccm.201610-2033le
Abstract: for the patients in the EBV group compared with –148 (SD, 862) in the control group (10). Although the relatively small sample size and short follow-up of 6 months are limitations of this study, the… read more here.
Keywords: nintedanib patients; idiopathic pulmonary; group; pulmonary fibrosis ... See more keywords